CompanyGraph
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
002399 · SZSE · China
hepalink.comFinancials as of FY2025
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $2.28B, above the global median of $1.15B
- FinancialsAltman Z-Score 3.16: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.41%Above 5Y avg (0.75%)
Annual Rate
CNY 0.14Paid annual
Payout Ratio
96.4%High
Payback Period
72.2 yr
Last Ex-Dividend
Jun 18, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
15.35BCNY2.28B · vs all stocks (USD)
Trailing P/E
40.62xRevenue (TTM)
5.42BCNY803.13M · vs all stocks (USD)
Profit Margin
7.03%Beta
0.2720xvs all stocks
52-Week Change
-22.66%vs all stocks
Market Capitalization
15.35BCNY2.28B · vs all stocks (USD)
Enterprise Value
15.55BCNY2.31B · vs all stocks (USD)
Trailing P/E
40.62xForward P/E
19.20xPrice to Sales (TTM)
2.86xPrice to Book (MRQ)
1.27xEnterprise to Revenue
2.87xEnterprise to EBITDA
16.57xGross Margin
34.15%Profit Margin
7.03%Operating Margin
14.35%Return on Assets (TTM)
2.21%Return on Equity (TTM)
3.04%Revenue (TTM)
5.42BCNY803.13M · vs all stocks (USD)
Revenue per Share (TTM)
3.69CNYUpdated Aug 19, 2026Quarterly Revenue Growth
-4.50%Gross Profit (TTM)
1.78BCNY263.95M · vs all stocks (USD)
EBITDA (TTM)
1.14BCNY168.99M · vs all stocks (USD)
Net Income (TTM)
380.47MCNY56.42M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
19.80%Operating Cash Flow (TTM)
1.55BCNY229.22M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
1.27BCNY188.15M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.1450CNYUpdated Aug 19, 2026Trailing Annual Dividend Yield
1.41%vs all stocks
5-Year Average Dividend Yield
0.75%vs all stocks
Payout Ratio
96.41%Minority Interest (Equity)
49.23MCNYFY2025 · Dec 31, 2025Revenue
5.48BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
3.74BCNYFY2025 · Dec 31, 2025Gross Profit
1.74BCNYFY2025 · Dec 31, 2025Operating Income
635.97MCNY94.31M · vs all stocks (USD)
Pre-tax Income
402.24MCNYFY2025 · Dec 31, 2025Income Tax Expense
59.60MCNYFY2025 · Dec 31, 2025Net Income
342.64MCNYFY2025 · Dec 31, 2025EBIT
473.68MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
1.14BCNYFY2025 · Dec 31, 2025Research & Development
226.16MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
478.17MCNYFY2025 · Dec 31, 2025Other Operating Expenses
47.29MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
38.27MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
71.44MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.2382CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.2382CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
1.47BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
1.47BSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
342.64MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
6.85MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
1.15BCNYFY2025 · Dec 31, 2025Free Cash Flow
1.03BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.19BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
342.64MCNYFY2025 · Dec 31, 2025Other Non-cash Items
85.27MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-132.51MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
858.24MCNYFY2025 · Dec 31, 2025Capital Expenditures
-118.93MCNYFY2025 · Dec 31, 2025Net Acquisitions
9.90MCNYFY2025 · Dec 31, 2025Purchase of Investments
-3.37BCNYFY2025 · Dec 31, 2025Sale of Investments
2.73BCNYFY2025 · Dec 31, 2025Other Investing Activity
-121.39MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-872.75MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
2.43BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-3.05BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-430.81MCNYFY2025 · Dec 31, 2025Other Financing Charges
-42.91MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-1.09BCNYFY2025 · Dec 31, 2025Shares Outstanding
1.47BSharesUpdated Aug 19, 2026Float Shares
411.03MSharesUpdated Aug 19, 2026% Held by Insiders
83.14%vs all stocks
% Held by Institutions
1.30%vs all stocks
Total Cash (MRQ)
3.50BCNY519.75M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.39CNYUpdated Aug 19, 2026Total Debt (MRQ)
3.26BCNY483.87M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2668xCurrent Ratio (MRQ)
2.15xBook Value per Share (MRQ)
8.30CNYUpdated Aug 19, 2026Total Assets
16.63BCNY2.47B · vs all stocks (USD)
Total Current Assets
9.15BCNYFY2025 · Dec 31, 2025Total Liabilities
4.55BCNYFY2025 · Dec 31, 2025Total Non-current Assets
7.48BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
598.22MCNYFY2025 · Dec 31, 2025Total Current Liabilities
3.95BCNYFY2025 · Dec 31, 2025Cash
1.19BCNYFY2025 · Dec 31, 2025Cash Equivalents
158.06MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.35BCNYFY2025 · Dec 31, 2025Other Short-term Investments
1.48BCNYFY2025 · Dec 31, 2025Accounts Receivable
1.37BCNYFY2025 · Dec 31, 2025Inventory
4.45BCNYFY2025 · Dec 31, 2025Accounts Payable
257.07MCNYFY2025 · Dec 31, 2025Short-term Debt
2.64BCNYFY2025 · Dec 31, 2025Other Current Liabilities
29.44MCNYFY2025 · Dec 31, 2025Long-term Debt
338.38MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
9.67MCNYFY2025 · Dec 31, 2025Common Stock (Book)
1.47BCNYFY2025 · Dec 31, 2025Retained Earnings
4.02BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
12.08BCNY1.79B · vs all stocks (USD)
52-Week Low
8.50CNYUpdated Aug 19, 202652-Week High
13.54CNYUpdated Aug 19, 202652-Week Change
-22.66%vs all stocks
Beta
0.2720xvs all stocks
50-Day MA
9.60CNYUpdated Aug 19, 2026200-Day MA
11.05CNYUpdated Aug 19, 2026Avg 10-Day Volume
10.05MSharesUpdated Aug 19, 2026Avg 30-Day Volume
6.97MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
0.2600CNYUpdated Aug 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 3.16: safe zoneNotable
Altman Z-Score: 3.16
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $2.28B, above the global median of $1.15BNotable
Market cap (USD): 2,276,096,282.852Global Median: 1,146,734,693.424
Revenue is $803.13M, above the global median of $520.53MNotable
Revenue (USD): 803,129,778.432Global Median: 520,528,949.311
Levered free cash flow is $188.15M, above the global median of $16.24MNotable
Levered free cash flow (USD): 188,150,739.405Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Voronoi, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jiangzhong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Nanobiotix S.A.
Tier 1ProductionApproval-Gated PipelineRule
Pavella Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Pfizer Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Agios Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Nektar Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Granules India Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Neogen Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow